Last reviewed · How we verify
Prevention of Breast Carcinoma
Approved treatments
- Evista · Eli Lilly
Raloxifene binds to estrogen receptors, acting as an agonist in bone and an antagonist in uterine and breast tissues. - Nolvadex · AstraZeneca (originally ICI)
Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density. - raloxifen · Organon and Co
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Breast Carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Breast Carcinoma treatment landscape brief
- Prevention of Breast Carcinoma treatment updates RSS
Frequently asked questions about Prevention of Breast Carcinoma
What drugs treat Prevention of Breast Carcinoma?
Tracked treatments include Evista, Nolvadex, raloxifen.
What is the treatment for Prevention of Breast Carcinoma?
Standard treatment for Prevention of Breast Carcinoma includes Evista, Nolvadex, raloxifen. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Breast Carcinoma patent cliff · Prevention of Breast Carcinoma CI report
- Treatment: Evista · Eli Lilly
- Treatment: Nolvadex · AstraZeneca (originally ICI)
- Treatment: raloxifen · Organon and Co
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing